Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease

The market for neurodegenerative disorder therapeutics is at a turning point. Despite a history of high failure rates—including in late-stage trials—the space has seen a recent spate of approvals, including Biogen and Ionis’ Qalsody for a subtype of amyotrophic lateral sclerosis (ALS) in April, following on the heels of Amylyx’s Relyvrio the previous September; Otsuka and Lundbeck’s Rexulti in May, the first drug for agitation in Alzheimer’s disease; and, most recently, Eisai and Biogen’s Leqembi for Alzheimer’s in July.